ASH Highlights
- Continuing Education
Deliver timely, disease-specific updates from the ASH Annual Meeting to equip hematologists, oncologists, and other clinicians with the knowledge to identify, understand, and apply emerging therapies in the treatment of blood cancers.
- Live Online
This course is taught online in real time.
$75
For a full list of profession pricing see below.
View All
Continuing Education
Earn up to:
6.00 AMA PRA Category 1 Credit(s) ™
View All
All evaluations and credit claims must be completed within 60 days of the course end date.
One Day
Please view the Schedule for a full description of the program.
On This Page
Overview
This activity is designed to educate hematologists, oncologists, and other clinicians on new developments in the diagnosis and treatment of all blood cancers. Through disease specific lectures, highlighting the most clinically relevant data presented at the ASH Annual Meeting, attendees will be able to identify and describe the emerging treatments available and to utilize these treatments available in their professional practice.
The American Society of Hematology’s annual meeting in December is the venue at which cutting edge therapeutic advances are presented publicly for the first time. Unfortunately, only a small fraction of practitioners can attend this meeting. It is therefore of vital importance for practitioners and, in turn, their patients to have access to emerging data in a timely fashion. At this one-day activity, attendees will receive relevant updates on advances in acute leukemia, myelodysplasia, myeloproliferative disorders, chronic myelogenous leukemia, chronic lymphocytic leukemia, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, multiple myeloma, Waldenstrom’s macroglobulinemia, coagulation disorders, hematopoietic stem cell transplantation, and CAR-T therapies.
Learning Objectives
- Describe an overview and highlight the recent medical advances present at the Annual Meeting of the American Society of Hematologists (ASH) which will help physicians achieve better patient outcomes.
- Recognize appropriate management and treatment options for hematologic malignancies.
- Utilize these approaches in routine clinical practice.
- Review new therapies and approaches in non-malignant hematology.
Developed and Offered By:
Continuing Education courses are developed by faculty from Harvard Medical School's teaching hospitals and accredited by Harvard Medical School. This course is offered by Dana Farber Cancer Insititue.
Who Should Participate
Nurses, Physician Assistants, Nurse Practitioners, Specialty Physicians, Primary Care Physicians, Other Health Care Professionals
Schedule
All agenda sessions are in Eastern Time.
Tuesday, January 26, 2027
Welcome and Introduction
9:00-9:10 am
Transplant Highlights
9:10-9:50 am
CAR-T Highlights
9:50-10:30 am
Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
10:30-11:10 am
Hematology Highlights
11:10-11:50 am
Break
11:50 am-12:05 pm
CLL Highlights
12:05-12:45 pm
Multiple Myeloma Highlights
12:45-1:25 pm
Lymphoma Highlights
1:25-2:05 pm
ASH 2025: ALL, CML and MPNs Highlights
2:05-2:45 pm
Closing Remarks
2:45-2:50 pm
Faculty
Harvard Medical School Continuing Education offers faculty who are international experts and leading educators in their fields. As a student in this course, you’ll have access to outstanding course directors and faculty.
Course Directors
Ann S. LaCasce
MD | Course Director
Inhye Ahn, MD
Jean Connors, MD
Jennifer Crombie, MD
Corey Cutler, MD
Daniel DeAngelo, MD, PhD
Tera Feldman, MA, PA-C
Yuxin Liu, MD
Caitlin Murphy, APRN, DNP, FNP
David Qualls, MD
Richard Stone, MD
Complete Your Registration
Started a registration? Log in to enroll today.
Request Information
Interested in learning more about this program? Sign up for details.
Course Fees
Registration Details
You may register through our secure online environment and will receive an email confirmation upon receipt of your payment. Virtual tuition includes electronic syllabus and access to recordings for 60 days after the course.
At the end of the registration process, a $10 non-refundable processing fee will be added to your registration.
| Role | Course Fee |
|---|---|
| Physician (MD/DO) | $75 |
| Nurse (RN/APRN) | $75 |
| Resident/Fellow | $75 |
Accreditation
The Harvard Medical School designates this live activity for a maximum of 6.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Harvard Medical School designates this Harvard Medical School designates this live activity for a maximum of 6.00 ANCC contact hours.
The National Commission on Certification of Physician Assistants (NCCPA) states that 6.00 AMA PRA Category 1 Credits™ are acceptable for continuing medical education requirements for recertification. We would also suggest that learners check with their state licensing board to ensure they accept reciprocity with AMA PRA Category 1 Credit™ for re-licensure.
The Royal College of Physicians and Surgeons of Canada recognizes conferences and workshops held outside of Canada that are developed by a university, academy, hospital, specialty society or college as accredited group learning activities.
The American Medical Association (AMA) has an agreement of mutual recognition of continuing medical education (CME) credit with the European Union of Medical Specialists (UEMS). Additional information regarding this agreement may be found on the Union of European Medical Specialists website.